Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextenza vs Prednisolone for PME in Diabetic Cataract Surgery
NCT04362241Phase 4Unknown
- Sponsor
- Ophthalmic Consultants of the Capital Region
- Start
- Aug 2020
- Primary completion
- Feb 2022
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ozurdex in pseudophakic cystoid macular edema (PCME) (2 arms), sponsored by Ophthalmic Consultants of the Capital Region. Primary endpoint: Incidence of Pseudophakic Macular Edema at 60 days. Status: unknown.
02
Drugs
ozurdex
03
Conditions
pseudophakic cystoid macular edema (PCME)
Beyond the preview
Go deeper on NCT04362241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362241.